Latest Breaking News On - Nektar therapeutics - Page 4 : comparemela.com

Nektar to Announce Financial Results for the First Quarter 2024 on Thursday, May 9, 2024, After Close of U.S.-Based Financial Markets

/PRNewswire/ Nektar Therapeutics (Nasdaq: NKTR) will announce its financial results for the first quarter 2024 on Thursday, May 9, 2024, after the close of.

San-francisco
California
United-states
Howard-robin
Vivian-wu
David-rosen
Nektar-therapeutics
Linkedin
Chief-executive-officer
Home-page
Nektar-earnings-call

Nektar to Announce Financial Results for the First Quarter 2024 on Thursday, May 9, 2024, After Close of U.S.-Based Financial Markets

SAN FRANCISCO, May 2, 2024 /PRNewswire/ Nektar Therapeutics will announce its financial results for the first quarter 2024 on Thursday, May 9, 2024, after the close of U.S.-based financial.

San-francisco
California
United-states
David-rosen
Vivian-wu
Howard-robin
Linkedin
Nektar-therapeutics
Chief-executive-officer
Home-page
Nektar-earnings-call

Nektar Therapeutics (NASDAQ:NKTR) Given Average Recommendation of "Hold" by Brokerages

Nektar Therapeutics (NASDAQ:NKTR – Get Free Report) has received an average rating of “Hold” from the five research firms that are currently covering the stock, Marketbeat Ratings reports. One equities research analyst has rated the stock with a sell rating, three have issued a hold rating and one has issued a buy rating on the […]

United-states
William-blair
Marquette-asset-management
Jefferies-financial-group
Nektar-therapeutics
Sg-americas-securities
Nasdaq
Citigroup-inc
Mackenzie-financial-corp
Cm-management
Get-free-report
Marketbeat-ratings

Analysts Set Nektar Therapeutics (NASDAQ:NKTR) Price Target at $3.50

Nektar Therapeutics (NASDAQ:NKTR – Get Free Report) has been assigned a consensus recommendation of “Hold” from the five ratings firms that are covering the firm, MarketBeat.com reports. One analyst has rated the stock with a sell rating, three have issued a hold rating and one has assigned a buy rating to the company. The average […]

United-states
William-blair
Citigroup-inc
Mackenzie-financial-corp
Nektar-therapeutics
Sg-americas-securities
Jefferies-financial-group
Marquette-asset-management
Barclays-plc
Nektar-therapeutics-company-profile
Get-free-report
Financial-group

Nektar to develop therapy candidate NKTR-0165 for MS, other disorders

Nektar to develop therapy candidate NKTR-0165 for MS, other disorders
multiplesclerosisnewstoday.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from multiplesclerosisnewstoday.com Daily Mail and Mail on Sunday newspapers.

Jonathan-zalevsky
Yanay-ofran
Nektar-therapeutics
Biolojic-design